Idenix HCV drug on hold; stock falls 25.7%
This article was originally published in Scrip
Executive Summary
Idenix Pharmaceuticals fell 25.7% in after-hours trading to $3.81 per share on 20 June based on the delayed start of clinical studies for the company's lead uridine nucleotide prodrug candidate IDX20963 following the US FDA's request for more preclinical safety data for the prospective hepatitis C virus (HCV) drug.
You may also be interested in...
Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Need a specific report? 1000+ reports available
Buy Reports